Biotechnology
Medical
Cancer Prevention

Kura Oncology

$15.36
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.47 (-2.97%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Kura Oncology and other stocks, options, ETFs, and crypto commission-free!

About

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. Read More The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.

Employees
43
Headquarters
San Diego, California
Founded
2014
Market Cap
603.88M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
252.51K
High Today
$15.90
Low Today
$15.33
Open Price
$15.90
Volume
42.63K
52 Week High
$22.00
52 Week Low
$10.20

Collections

Biotechnology
Medical
Cancer Prevention
Health
Research And Development
Biopharmaceutical
Pharmaceutical
2015 IPO

News

Simply Wall StMar 7

Did You Miss Kura Oncology’s Impressive 222% Share Price Gain?

The most you can lose on any stock (assuming you don’t use leverage) is 100% of your money. But if you buy shares in a really great company, you can more than double your money. For instance the Kura Oncology, Inc. (NASDAQ:KURA) share price is 222% higher than it was three years ago. Most would be happy with that. But it’s down 9.9% in the last week. It may be that the recent financial results disappointed, so check out the latest revenue and profit numbers on in our company report. See our latest analysis...

147
Seeking AlphaMar 5

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q4 2018 Results - Earnings Call Transcript

Kura Oncology, Inc. (NASDAQ:KURA) Q4 2018 Results Earnings Conference Call March 5, 2019 4:30 PM ET Company Participants Pete De Spain - VP, IR and Corporate Communications Troy Wilson - President and CEO Marc Grasso - CFO and Chief Business Officer Antonio Gualberto - Head, Development and Chief Medical Officer Conference Call Participants Jonathan Chang - STB Leerink Pamela Barendt - Cowen Alexander Duncan - Piper Jaffray Jay Olson - Oppenheimer Joel Beatty - Citi Operator Good day, ladies an...

22
Yahoo FinanceFeb 19

Detailed Research: Economic Perspectives on Tesla, Kura Oncology, ASML Holding N.V, Applied Industrial Technologies, Raven Industries, and Intra-Cellular Therapies — What Drives Growth in Today's Comp

NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tesla, Inc. (TSLA), Kura Oncology, Inc. (KURA), ASML Holding N.V. (ASML), Applied Industrial Technologies, Inc. (AIT), Raven Industries, Inc. (RAVN), and Intra-Cellular Therapies Inc. (ITCI), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified ...

84

Earnings

-$0.46
-$0.42
-$0.39
-$0.35
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.